Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting

Molecular Pharmaceutics

Volumn 5, Issue 5, 2008, Pages 776-786

  Cuchelkar, Vaikunth ^a   Kopečková, Pavla ^a,b   Kopeček, Jindřich ^a,b  

^a Department of Electrical and Computer Engineering   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

HPMA copolymer; Mesochlorin e6; Mitochondrial targeting; TPP; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER MESOCHLORIN E6 MONOETHYLENEDIAMINE CONJUGATE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MICROINJECTION; MITOCHONDRION; OVARY CANCER; PRIORITY JOURNAL;

ACRYLAMIDES; ANTINEOPLASTIC AGENTS; BORON COMPOUNDS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LYSINE; MESOPORPHYRINS; MITOCHONDRIA; MOLECULAR STRUCTURE; ORGANOPHOSPHORUS COMPOUNDS; OVARIAN NEOPLASMS;

EID: 56049088297     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800019g     Document Type: Article

References (58)

1. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46, 6387-6392.
2. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2, 750-763.
3. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discovery 2003, 2, 347-360.
4. Kopeček, J.; Kopečková, P.; Minko, T.; Lu, Z. HPMA copolymeranticancer drug conjugates: Design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 2000, 50, 61-81.
5. Shen, W. C.; Ryser, H. J. cis-Aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 1981, 102, 1048-1054.
6. Willner, D.; Trail, P. A.; Hofstead, S. J.; King, H. D.; Lasch, S. J.; Braslawsky, G. R.; Greenfield, R. S.; Kaneko, T.; Firestone, R. A. (6-Maleimidocaproyl)hydrazone of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjugate Chem. 1993, 4, 521-527.
7. Rejmanová, P.; Kopeček, J.; Pohl, J.; Baudyš, M.; Kostka, V. Polymers containing enzymically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 1983, 184, 2009-2020.
8. Shen, W. C.; Ryser, H. J.; LaManna, L. Disulfide spacer between methotrexate and poly(D-lysine). A probe for exploring the reductive process in endocytosis. J. Biol. Chem. 1985, 260, 10905-10908.
9. 6 conjugates. Macromol Biosci. 2008, 8, 375-383.
10. Omelyanenko, V.; Gentry, C.; Kopečková, P.; Kopeěk, J. HPMA copolymer-anticancer drug-OV-Th16 antibody conjugates. II Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 1998, 75, 600-608.
11. Wallace, D. C. Mitochondria and cancer: Warburg addressed. Cold Spring Harbor Symp. Quant. Biol. 2005, 70, 363-374.
12. Alirol, E.; Martinou, J. C. Mitochondria and cancer: Is there a morphological connection. Oncogene 2006, 25, 4706-4716.
13. Patterson, S. D.; Spahr, C. S.; Daugas, E.; Susin, S. A.; Irinopoulou, T.; Koehler, C.; Kroemer, G. Mass spectrometric identification of proteins released from mitochondria undergoing permeability transition. Cell Death Differ. 2000, 7, 137-144.
14. Ravagnan, L.; Roumier, T.; Kroemer, G. Mitochondria, the killer organelles and their weapons. J. Cell. Physiol. 2002, 192, 131-137.
15. Murphy, M. P. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol. 1997, 15, 326-330.
16. Callahan, J.; Kopeček, J. Semitelechelic HPMA copolymers functionalized with triphenylphosphonium as drug carriers for membrane transduction and mitochondrial localization. Biomacromolecules 2006, 7, 2347-2356.
17. Peng, Q.; Moan, J.; Nesland, J. M. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct. Pathol. 1996, 20, 109-129.
18. Deroose, F. D.; De Clercq, P.J. Novel enantioselective syntheses of (+)-biotin. J. Org. Chem. 1995, 60, 321-330.
19. Kato, K.; Ohkawa, S.; Terao, S.; Terashita, Z.; Nishikawa, K. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. J. Med. Chem. 1985, 28, 287-294.
20. Warburg, O. On respiratory impairment in cancer cells. Science 1956, 124, 269-270.
21. Behrend, L.; Henderson, G.; Zwacka, R. M. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans. 2003, 31, 1441-1444.
22. Gillies, R. J.; Gatenby, R. A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev. 2007, 26, 311-317.
23. Tan, D. J.; Bai, R. K.; Wong, L. J. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res. 2002, 62, 972-976.
24. Liu, V. W.; Shi, H. H.; Cheung, A. N.; Chiu, P. M.; Leung, T. W.; Nagley, P.; Wong, L. C.; Ngan, H. Y. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res. 2001, 61, 5998-6001.
25. Polyak, K.; Li, Y.; Zhu, H.; Lengauer, C.; Willson, J. K.; Markowitz, S. D.; Trush, M. A.; Kinzler, K. W.; Vogelstein, B. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet. 1998, 20, 291-293.
26. Horton, T. M.; Petros, J. A.; Heddi, A.; Shoffner, J.; Kaufman, A. E.; Graham, S. D., Jr.; Gramlich, T.; Wallace, D. C. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer 1996, 15, 95-101.
27. Yeh, J. J.; Lunetta, K. L.; van Orsouw, N. J.; Moore, F. D., Jr.; Mutter, G. L.; Vijg, J.; Dahia, P. L.; Eng, C. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 2000, 19, 2060-2066.
28. Manion, M. K.; Fry, J.; Schwartz, P. S.; Hockenbery, D. M. Small-molecule inhibitors of Bcl-2. Curr. Opin. Invest. Drugs 2006, 7, 1077-1084.
29. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M.D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681.
30. Kagawa, S.; Gu, J.; Swisher, S. G.; Ji, L.; Roth, J. A.; Lai, D.; Stephens, L. C.; Fang, B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res. 2000, 60, 1157-1161.
31. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004, 305, 1466-1470.
32. Ravagnan, L.; Marzo, L.; Costantini, P.; Susin, S. A.; Zamzami, N.; Petit, P. X.; Hirsch, F.; Goulbern, M.; Poupon, M. F.; Miccoli, L.; Xie, Z.; Reed, J. C.; Kroemer, G. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 1999, 18, 2537-2546.
33. Ahn, H. J.; Kim, Y. S.; Kim, J. U.; Han, S. M.; Shin, J. W.; Yang, H. O. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J. Cell. Biochem. 2004, 91, 1043-1052.
34. Andre, N.; Carre, M.; Brasseur, G.; Pourroy, B.; Kovacic, H.; Briand, C.; Braguer, D. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 2002, 532, 256-260.
35. Cullen, K. J.; Yang, Z.; Schumaker, L.; Guo, Z. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr. 2007, 39, 43-50.
36. Anderson, K. C.; Boise, L. H.; Louie, R.; Waxman, S. Arsenic trioxide in multiple myeloma: Rationale and future directions. Cancer J. 2002, 8, 12-25.
37. Fantin, V. R.; Leder, P. Mitochondriotoxic compounds for cancer therapy. Oncogene 2006, 25, 4787-4797.
38. Palmieri, F.; Bisaccia, F.; Capobianco, L.; Dolce, V.; Fiermonte, G.; Iacobazzi, V.; Indiveri, C.; Palmieri, L. Mitochondrial metabolite transporters. Biochim. Biophys. Acta 1996, 1275, 127-132.
39. Horwich, A. L.; Kalousek, F.; Mellman, I.; Rosenberg, L. E. A leader peptide is sufficient to direct mitochondrial import of a chimeric protein. EMBO J. 1985, 4, 1129-1135.
40. Flierl, A.; Jackson, C.; Cottrell, B.; Murdock, D.; Seibel, P.; Wallace, D. C. Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Mol. Ther. 2003, 7, 550-557.
41. Vestweber, D.; Schatz, G. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature 1989, 338, 170-172.
42. Chinnery, P. F.; Taylor, R. W.; Diekert, K.; Lill, R.; Tumbull, D. M.; Lightowlers, R. N. Peptide nucleic acid delivery to human mitochondria. Gene Ther. 1999, 6, 1919-1928.
43. D'Souza, G. G.; Rammohan, R.; Cheng, S. M.; Torchilin, V. P.; Weissig, V. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J. Controlled Release 2003, 92, 189-197.
44. Muratovska, A.; Lightowlers, R. N.; Taylor, R. W.; Turnbull, D. M.; Smith, R. A.; Wilce, J. A.; Martin, S. W.; Murphy, M. P. Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: Implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res. 2001, 29, 1852-1863.
45. Jauslin, M. L.; Meier, T.; Smith, R. A.; Murphy, M. P. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003, 17, 1972-1974.
46. Morgan, J.; Oseroff, A. R. Mitochondria-based photodynamic anticancer therapy. Adv. Drug Delivery Rev. 2001, 49, 71-86.
47. Moan, J.; Berg, K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol. 1991, 53, 549-553.
48. 6 conjugates in a human ovarian carcinoma. J. Controlled Release 2001, 74, 269-273.
49. 6 conjugates. Photochem. Photobiol. 2003, 77, 645-652.
50. Kessel, D.; Luo, Y. Photodynamic therapy: A mitochondrial inducer of apoptosis. Cell Death Differ. 1999, 6, 28-35.
51. Kessel, D.; Castelli, M. Evidence that bcl-2 is the target of three photosensitizers that induce a rapid apoptotic response. Photochem. Photobiol. 2001, 74, 318-322.
52. Gardner, L. C.; Smith, S. J.; Cox, T. M. Biosynthesis of delta-aminolevulinic acid and the regulation of heme formation by immature erythroid cells in man. J. Biol. Chem. 1991,266, 22010-22018.
53. Barge, J.; Decreau, R.; Julliard, M.; Hubaud, J. C.; Sabatier, A. S.; Grob, J. J.; Verrando, P. Killing efficacy of a new silicon phthalocyanine in human melanoma cells treated with photodynamic therapy by early activation of mictochondrion-mediated apoptosis. Exp. Dermatol. 2004, 13, 33-44.
54. Kessel, D.; Luguya, R.; Vicente, M. G. Localization and photodynamic efficacy of two cationic porphyrins varying in charge distributions. Photochem. Photobiol. 2003, 78, 431-435.
55. Lai, J. C.; Lo, P. C.; Ng, D. K.; Ko, W. H.; Leung, S. C.; Fung, K. P.; Fong, W. P. BAM-SiPc, a novel agent for photodynamic therapy, induces apoptosis in human hepatocarcinoma HepG2 cells by a direct mitochondrial action. Cancer Biol. Ther. 2006,5,413-418.
56. Li, R.; Bounds, D. J.; Granville, D.; Ip, S. H.; Jiang, H.; Margaron, P.; Hunt, D. W. Rapid induction of apoptosis in human keratinocytes with the photosensitizer QLT0074 via a direct mitochondrial action. Apoptosis 2003, 8, 269-275.
57. Peng, T. I.; Chang, C. J.; Guo, M. J.; Wang, Y. H.; Yu, J. S.; Wu, H. Y.; Jou, M. J. Mitochondrion-targeted photosensitizer enhances the photodynamic effect-induced mitochondrial dysfunction and apoptosis. Ann. N.Y Acad. Sci. 2005, 1042, 419-428.
58. Hilf, R. Mitochondria are targets of photodynamic therapy. J, Bioenergy. Biomembr. 2007, 39, 85-89.